30 May 2016

Mineral group plans £20m float

Robert Tyerman

Aussie-listed Greenland Minerals & Energy wants to raise £20m and float on AIM

Aussie-listed Greenland Minerals & Energy wants to raise £20m and float on AIM

Aussie-listed Greenland Minerals and Energy is planning a flotation on the London Stock Exchange to raise £20 million for a £1.4 billion world-class rare earth and uranium project at Kvanefjeld in Greenland. An independent pre-feasibility study has suggested that the project could run for 23 years with capital expenditure of $2.3 billion (£1.4 billion), generating an operating surplus of $600 million and paying back the initial outlay in five years.

Greenland Minerals, valued Down Under at almost £70 million at the equivalent of 30p, owns 61 per cent of the Kvanefjeld licence, with options to take that to 90 or 100 per cent, says managing director Rod McIllree. Having hired Evolution Securities to advise on the London issue and considering adding J.P. Morgan or another group to the team, the company would spend the money on a definitive feasibility study.

With Kvanefjeld containing an estimated 4.9 million tonnes of rare earth oxides (used in high-tech and environmental applications, including flat display panels, hybrid cars and wind turbines) and 120,000 tonnes of uranium oxide, U3O8, the pre-feasibility study envisages annual production of 43,729 tonnes of rare earth oxide and 3,895 tonnes of U3O8. McIllree insists that ‘the uranium will pay for everything’, but he sees rare earths as the major profit generator.

Describing rare earth carbonates, now trading at around US$13 (810p) a kilogram, as ‘the new market darling’, McIllree expects a favourable political reaction. Greenland Minerals has made former Greenland prime minister Lars Emil Johansen chairman of its local subsidiary and he contends the territory is anxious to cut unemployment as it seeks greater autonomy from Denmark.

This should be a float to watch.

Tags: Fundraisings, New Issues

Cash Shells 2015

Published in September 2015 this annual research report provides a comprehensive overview of cash shells on the Main Market, AIM and PLUS landscape. Order your copy today

 

Superb investment toolkit for private investors

SharePad is the new web-based service from ShareScope. Easier to use and more powerful. Perfect for tablets, Macs and Windows PC. Covers ALL your investment requirements.

Growth Company Investor: free trial

Since 2008, our share tips outperformed the benchmark by 281%. Take a free trial and get access to our recommendations today. Start free trial now.

Directors' Pay on AIM 2015

The most comprehensive review of AIM directors' pay available, and this year includes a record sample of 1000+ AIM-quoted companies. The full report is available to order for £385 + VAT. Click here for more info

 

Latest small-cap and growth company news

Daily coverage of small-cap company stocks on London's junior markets AIM and PLUS, breaking news, stock research and latest share price information for investors. Full sector coverage with all the latest news on smaller listed companies, updated several times a day with financial reports, trading statements and links to further web resources.

Popular News

Latest News

Motif Bio and the ticking timebomb

The recently published O'Neill report on antimicrobial resistance shows it to be a ticking timebomb. Resistance to antibiotics raises the prospect of 10 million deaths a year by 2050. This is a big opportunity for AIM listed Motif Bio (AIM: MTFB).      

Make mine a double!

Fevertree Drinks (AIM: FEVR) has been one of the most spectacular new issues on AIM in recent years, rising 412 per cent from the float price in late 2014. Today’s trading update served to emphasise why the shares are doing so well and drove them up another 15 per cent.

Fox Marble might be worth the wait 

Fox Marble (AIM: FOX) has raised £2 million through a placing at 10p. The funds will be mainly used to complete its long-delayed marble processing factory in Kosovo. Fox has an exciting story but unfortunately is lagging way behind its original roadmap to profitability.

Business as usual at XL Media 

XL Media (AIM: XLM) has announced the result of its strategic review. I hope no one was holding their breath, because the conclusion is to carry on as usual! The good news is that trading is said to have ‘maintained its excellent start to 2016’.

A Quantum of solace

Quantum Pharma (AIM: QP.) committed the cardinal sin of overpromising and under-delivering during its first year on AIM. New products took longer to come through the regulatory process than expected, which caused downgrades and a share price collapse from a high of 172p last June to the current 58p. However results for the financial year which ended in January suggest the company is getting to grips with the problems in its Niche Pharmaceuticals division.

Elecosoft constructs a strategy for growth 

Elecosoft (AIM: ELCO) is a specialist software company serving architects and builders. It used to be a much larger business but sold out of its building materials businesses four years ago to focus on its software arm. The challenge now is to generate some revenue growth and move off a sales plateau which has been in place since then.

More News